Despite media reports announcing the retraction of a much-criticized study of whether women with endometriosis were more attractive than other women, the study has yet to be retracted by the journal.
A group of researchers in India whose findings in a 2015 paper evidently looked too good to be true have received an expression of concern because they claim Covid-19 restrictions have made it impossible to recover their raw data.
A former scientist at Wayne State University in Detroit who lost his PhD from the institution has agreed to a 10-year ban on any federally funded research after being found guilty of misconduct.
The U.S. Office of Research Integrity says Zhiwei Wang fabricated data in nine grants funded by the National Institutes of Health, as well as in three grant applications and his 2006 doctorate.
The journal that allowed a bizarre article linking Covid-19 to 5G cell phone waves to “slip through the net” now blames rigged peer review for the fishy paper.
As we reported last month, the journal initially simply withdrew the article without explanation. But the publisher, Biolife, then provided us with a few less-than-satisfying excuses, such as:
Overweight people are more dishonest, women with endometriosis are more attractive, and affirmative action needs to stop: Papers with these three conclusions have come under intense scrutiny on social media in recent days, with at least one retracted.
First up, a study — widely criticized for being sexist — which claimed to find that
Women with rectovaginal endometriosis were judged to be more attractive than those in the two control groups. Moreover, they had a leaner silhouette, larger breasts, and an earlier coitarche.
A legal journal has retracted a 2019 article on the facial genetics of ethnic minorities in China for ethics violations, and the publisher, Springer Nature, is investigating more than two dozen other articles for similar concerns.
The article, “Y Chromosomal STR haplotypes in Chinese Uyghur, Kazakh and Hui ethnic groups and genetic features of DYS448 null allele and DYS19 duplicated allele,” appeared in the International Journal of Legal Medicine.
After whistleblowers in China prompted the retraction of a 2018 paper that overstated the number of patients treated in a study, another journal says it’s investigating a second article by the same group.
Last month, as we reported, the Journal of Surgical Oncology retracted “Long‐term outcomes of 530 esophageal squamous cell carcinoma patients with minimally invasive Ivor Lewis esophagectomy.” The move was prompted by whistleblowers who notified the journal that the 530 cases could not have been performed at the authors’ institution, Zhejiang University, in Hangzhou.
After our post, a Twitter user pointed us to a second article by the group, in BMC Cancer, which claimed to report data on 697 subjects over just one additional year — a highly improbable figure.
As Retraction Watch readers may recall, we’ve been highlighting — and championing — the work of anonymous whistleblowers throughout the 10-year history of the blog. Our support for such anonymity, however, is not universally shared.
In 2011, for example, in our column at Lab Times (unfortunately no longer online), we wrote:
Xavier Argemi first heard the claim that tea made from artemisia herbs could be useful in the treatment of malaria from a TV documentary in 2017.
The documentary, featuring Lucile Cornet-Vernet, the director of the La Maison de l’Artemisia, a non-profit organization that grows artemisia and promotes its use in centers across Africa, focused on the Democratic Republic of the Congo (DRC). The film claimed that for decades major pharmaceutical companies have been profiting from expensive malaria drugs based on artemisinin — the antimalarial for which Tu Youyou won a Nobel Prize in 2015, after distilling it from the Artemisia annua plant — while the tea itself, an ancient Chinese herbal remedy, was just as effective at treating the disease.
His interest piqued, Argemi reached out to Cornet-Vernet, an orthodontist at Paris’ Descartes University. She shared with him the unpublished manuscript of a study — their first large-scale clinical trial — which she said showed that artemisia outperformed a go-to treatment for schistosomiasis, a different parasite-induced disease.
Argemi immediately saw red flags. “I am not a specialist of malaria or schistosomiasis, but when I read the study I was simply totally surprised by the number of inconsistencies at the very first read,” Argemi, of the Clinique Axium in Strasbourg, France, told Retraction Watch by email.
